Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-2xdlg Total loading time: 0 Render date: 2024-06-30T10:34:39.907Z Has data issue: false hasContentIssue false

Chapter 13 - Psychopharmacology

from Section 3 - Interventions

Published online by Cambridge University Press:  05 March 2016

By
Stephen Ruedrich
Edited by
Colin Hemmings  and
Nick Bouras
Colin Hemmings
Affiliation:
Albion Place Medical Centre
Nick Bouras
Affiliation:
Institute of Psychiatry, London
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Psychiatric and Behavioral Disorders in Intellectual and Developmental Disabilities , pp. 139 - 150
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agarwal, V., Sitholey, P., Kumar, S., et al. (2001). Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation. Mental Retardation, 39, 259–267.2.0.CO;2>CrossRefGoogle ScholarPubMed
Aman, M.G., Benson, B.A., Farmer, C.A., et al. (2007). Project MED: effects of a medication education booklet series for individuals with intellectual disabilities. Intellectual and Developmental Disabilities, 45, 33–45.CrossRefGoogle ScholarPubMed
Aman, M.G., Farmer, C.A., Hollway, J., et al. (2008). Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child and Adolescent Clinics of North America, 17, 13–38.CrossRefGoogle ScholarPubMed
Aman, M.G., Smith, T., Arnold, L.E., et al. (2014). A review of atomoxetine effects in young people with developmental disabilities. Research in Developmental Disabilities, 35, 1412–1424.CrossRefGoogle ScholarPubMed
Antonacci, D.J. and Attiah, N. (2008). Diagnosis and treatment of mood disorders in adults with developmental disabilities. Psychiatric Quarterly, 79, 171–192.Google Scholar
Beach, S.R., Celano, C.M., Noseworthy, P.A., et al. (2013). QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics, 54, 1–13.Google Scholar
Boada, R., Hutaff-Lee, C., Schrader, A., et al. (2012). Antagonism of NMDA receptors as a potential treatment for Down's syndrome: a pilot randomized controlled trial. Translational Psychiatry, 2, e141.CrossRefGoogle ScholarPubMed
Canitano, R. (2014). New experimental treatments for core social domain in autism spectrum disorders. Frontiers in Pediatrics, 2, 61.Google Scholar
Costa, A.C. and Scott-McKean, J.J. (2013). Prospects for improving brain function in individuals with Down's syndrome. CNS Drugs, 27, 672–702.Google Scholar
Courtemanche, A.B., Schroeder, S.R., Sheldon, J.B. (2011). Designs and analyses of psychotropic and behavioural interventions for the treatment of problem behaviour among people with intellectual and developmental disabilities. American Journal on Intellectual and Developmental Disabilities, 116, 315–328.Google Scholar
Davis, E., Saeed, S.A., Antonacci, D.J. (2008). Anxiety disorders in persons with developmental disabilities: empirically informed diagnosis and treatment. Psychiatric Quarterly, 79, 249–263.Google Scholar
De Kuijper, G., Mulder, H., Evenhuis, H., et al. (2013). Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics. Research in Developmental Disabilities, 34, 2799–2809.Google Scholar
De Leon, J., Greelee, B., Barber, J., et al. (2009). Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Research in Developmental Disabilities, 30, 613–669.CrossRefGoogle ScholarPubMed
Deb, S. and Unwin, G.L., (2007). Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature. Current Opinion in Psychiatry, 20, 461–466.Google Scholar
Deb, S., Sohanpal, S.K., Soni, R., et al. (2007). The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. Journal of Intellectual Disability Research, 51, 766–777.CrossRefGoogle ScholarPubMed
Deb, S., Chaplin, R., Sohanpal, S., et al. (2008). The effectiveness of mood stabilizers and antiepileptic medications for the management of behaviour problems in adults with intellectual disability: a systematic review. Journal of Intellectual Disability Research, 52, 107–113.CrossRefGoogle ScholarPubMed
Deb, S., Salvadoe-Carulla, J., Barnhill, J., et al. (2010). Problem Behaviours in Adults with Intellectual Disabilities: An International Guide for Using Medication. The World Psychiatric Association (WPA): Section Psychiatry of Intellectual Disability. At: http://www.wpanet.org/uploads/Sections/Psychiatry_Intellectual/WPA-SPID-International-Guide.pdfGoogle Scholar
Doig, J., McLennan, J.D., Gibbard, W.B. (2008). Medication effects on symptoms of attention-deficit/hyperactivity disorder in children with fetal alcohol spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 18, 365–371.Google Scholar
Dykens, E. and Shah, B. (2003). Psychiatric disorders in Prader–Willi syndrome: epidemiology and management. CNS Drugs, 17, 167–178.CrossRefGoogle ScholarPubMed
Edelsohn, G.A., Schuster, J.M., Castelnovo, K., et al. (2014). Psychotropic prescribing for persons with intellectual disabilities and other psychiatric disorders. Psychiatric Services, 65, 201–207.Google Scholar
Fletcher, R., Loschen, E., Stavrakaki, C. (eds.) (2007). Diagnostic Manual – Intellectual Disability (DM-ID): A Textbook of Diagnosis of Mental Disorders in Persons with Intellectual Disability. Kingston, NY: NADD Press.Google Scholar
Frighi, V., Stephenson, M.T., Moroval, A., et al. (2011). Safety of antipsychotics in people with intellectual disability. British Journal of Psychiatry, 199, 289–295.CrossRefGoogle ScholarPubMed
Frankel, F., Paley, B., Marquardt, R., et al. (2006). Stimulants, neuroleptics, and children's friendship training for children with fetal alcohol spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 16, 777–789.Google Scholar
Ghanizadeh, A., Sahraeizadeh, A., Berk, M., (2014). A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development, 45, 185–192.CrossRefGoogle ScholarPubMed
Gormez, A., Rana, F., Varghese, S. (2014). Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities: abridged republication of a Cochrane systematic review. Journal of Psychopharmacology, 28, 624–632CrossRefGoogle ScholarPubMed
Gothelf, D., Schneider, M., Green, T., et al. (2013). Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome. A longitudinal 2-site study. Journal of the American Academy of Child and Adolescent Psychiatry, 52, 1192–1203.Google Scholar
Green, T., Weinberger, R., Diamond, A., et al. (2011). The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. Journal of Child and Adolescent Psychopharmacology, 21, 589–595.Google Scholar
Green, T., Avda, S., Dotan, I., et al. (2012). Phenotypic psychiatric characterization of children with Williams syndrome and response of those with ADHD to methylphenidate treatment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 159B, 13–20.CrossRefGoogle ScholarPubMed
Hagerman, R., Des-Portes, V., Gasparini, F., et al. (2014). Translating molecular advances in Fragile X syndrome into therapy: a review. Journal of Clinical Psychiatry, 75, e294–e307.Google Scholar
Handen, B.L., Sahl, R., Hardan, A.Y. (2008). Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics, 29, 303–308.CrossRefGoogle ScholarPubMed
Hanney, M., Prasher, V., Williams, N., et al. (2012). Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomized, double-blind, placebo-controlled trial. Lancet, 379, 528–536.Google Scholar
Harris, J.C. (2006). Intellectual Disability. New York, NY: Oxford University Press.Google Scholar
Hurwitz, R., Blackmore, R., Hazell, P., et al. (2012). Tricyclic antidepressants for autism spectrum disorder (ASD) in children and adolescents. Cochrane Database of Systematic Reviews, 3, CD008372.Google Scholar
James, S., Montgomery, P., Williams, K. (2011). Omega-3 fatty acids supplementation for autism spectrum disorders (ASD) Cochrane Database for Systematic Reviews, 11, CD007992.Google Scholar
Jones, R.M., Arlidge, J., Gillham, R., et al. (2011). Efficacy of mood stabilizers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. British Journal of Psychiatry, 198, 93–98.Google Scholar
Kalachnik, J.E. and Hanzel, T.E. (2001). Behavioral side effects of barbiturate antiepileptic drugs in individuals with mental retardation and developmental disabilities. National Association for Dual Diagnosis Bulletin, 4, 49–55.Google Scholar
Kalachnik, J.E., Hanzel, T.E., Sevenich, R., et al. (2002). Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. American Journal on Mental Retardation, 107, 376–410.2.0.CO;2>CrossRefGoogle ScholarPubMed
King, B.H (2007). Psychopharmacology in intellectual disabilities. In Bouras, N. and Holt, G. (eds.), Psychiatric and Behavioural Disorders in Intellectual and Developmental Disabilities, second edition. Cambridge: Cambridge University Press.Google Scholar
King, B.H., Hollander, E., Sikich, L., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry, 66, 583–590.CrossRefGoogle ScholarPubMed
Kishnani, P.S., Sommer, B.R., Handen, B.L., et al. (2009). The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. American Journal of Medical Genetics Part A, 149, 1641–1654.CrossRefGoogle Scholar
Kishnani, P.S., Heller, J.H., Spiridigliozzi, G.A., et al. (2010). Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17. American Journal of Medical Genetics Part A, 152, 3028–3035.CrossRefGoogle Scholar
Kondoh, T., Kanno, A., Itoh, H., et al. (2011). Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double blind, placebo-controlled trial. International Journal of Psychiatry in Medicine, 41, 71–89.CrossRefGoogle ScholarPubMed
Levitas, A. (2003). Reader response to Zarcone et al. (2001) “Effects of risperidone on aberrant behavior in persons with developmental disabilities: I. A double-blind crossover study using multiple measures.” American Journal on Mental Retardation, 108, 212–216.Google Scholar
Levitas, A.S., Hurley, A.D., Pary, R. (2001). The mental status examination in patients with mental retardation and developmental disabilities. Mental Health Aspects of Developmental Disability, 41, 1–30.Google Scholar
Lott, I.T., Doran, E., Nguyen, V.Q., et al. (2011). Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. American Journal of Medical Genetics Part A, 155, 1939–1948.CrossRefGoogle Scholar
Martens, M.A., Seyfer, D.L., Andridge, R.R., et al. (2012). Parent report of antidepressant, anxiolytic, and antipsychotic medication use in individuals with Williams syndrome: effectiveness and adverse effects. Research in Developmental Disabilities, 33, 2106–2121.CrossRefGoogle ScholarPubMed
Matson, J.L. and Mahan, S. (2010). Antipsychotic drug side effects for persons with intellectual disability. Research in Developmental Disabilities, 31, 1570–1576.CrossRefGoogle ScholarPubMed
McGrother, C.W., Bhaumik, S., Thorp, C.F., et al. (2006). Epilepsy in adults with intellectual disabilities: prevalence, associations, and service implications. Seizure, 15, 376–386.Google Scholar
Menolascino, F.J., Ruedrich, S.L., Golden, C.J., et al. (1985). Diagnosis and pharmacotherapy of schizophrenia in the retarded. Psychopharmacology Bulletin, 21, 316–322.Google ScholarPubMed
Oliver-Africano, P., Murphy, D., Tyrer, P. (2009). Aggressive behavior in adults with intellectual disability: defining the role of drug treatment. CNS Drugs, 23, 903–913.CrossRefGoogle ScholarPubMed
Posey, D.J., Aman, M.G., McCracken, J.T., et al. (2007). Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biological Psychiatry, 15, 538–544.Google Scholar
Reiss, S. and Aman, M.G. (eds.) (1998). Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: Ohio State University, Nisonger Center Press.Google Scholar
Rojahn, J., Matson, J.L., Naglieri, J.A., et al. (2004). Relationships between psychiatric conditions and behavior problems among adults with mental retardation. American Journal on Mental Retardation, 109, 21–33.2.0.CO;2>CrossRefGoogle ScholarPubMed
Rossignol, D.A. and Frye, R.E. (2013). Melatonin in autism spectrum disorders. Current Clinical Pharmacology, 8, 1–9.Google Scholar
Rowles, B.M. and Findling, R.L. (2010). Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders. Developmental Disabilities Research Reviews, 16, 273–282.Google Scholar
Roy, A., Roy, M., Deb, S., et al. (2015). Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. Journal of Intellectual Disability Research, 59(4), 293–306.Google Scholar
Rueda, J.R., Ballesteros, J., Tejada, M.I. (2009). Systematic review of pharmacological treatments in Fragile X syndrome. BMC Neurology, 9, 53.CrossRefGoogle ScholarPubMed
Ruedrich, S.L. and Erhardt, L. (1999). Beta-adrenergic blockers in mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 290–298.Google Scholar
Ruedrich, S.L., Hurley, A., Sovner, R. (2001). Treatment of mood disorders in mentally retarded persons. In Dosen, A. and Day, K. (eds.), Treating Mental Illness and Behavior Disorders in Children and Adults with Mental Retardation. Washington, DC: American Psychiatric Press.Google Scholar
Rush, A.J. and Frances, A. (eds.) (2000). The Expert Consensus Guideline Series. Treatment of psychiatric and behavioral problems in mental retardation. American Journal on Mental Retardation, 105 (Issue 3, Special Issue), 159–228.Google Scholar
Schroeder, S.R., Bouras, N., Ellis, C.R., et al. (1998). Past research on psychopharmacology of people with mental retardation and intellectual disabilities. In Reiss, S. and Aman, M.G. (eds.), Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: Ohio State University, Nisonger Center Press.Google Scholar
Schupf, N. and Sergievsky, G.H. (2002). Genetic and host factors for dementia in Down syndrome. British Journal of Psychiatry, 180, 405–410.Google Scholar
Shapira, N., Lessig, M., Lewis, M. et al. (2004). Effects of topiramate in adults with Prader–Willi syndrome. American Journal on Mental Retardation, 109, 301–309.Google Scholar
Simonoff, E., Taylor, E., Baird, G., et al. (2013). Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Journal of Child Psychology and Psychiatry, 54, 527–535.Google Scholar
Sipes, M., Matson, J.L., Belva, B., et al. (2011). The relationship among side effects associated with anti-epileptic medications in those with intellectual disability. Research in Developmental Disabilities, 32, 1646–1651.Google Scholar
Sohanpal, S.K., Deb, S., Thomas, R., et al. (2007). The effectiveness of antidepressant medication in the management of behaviour problems in adults with intellectual disabilities: a systematic review. Journal of Intellectual Disability Research, 51, 750–765.CrossRefGoogle ScholarPubMed
Tauber, M., Mantoulan, C., Copet, P., et al. (2011). Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader–Willi syndrome: a randomized placebo-controlled trial in 24 patients. Orphanet Journal of Rare Diseases, 6, 47.Google Scholar
Torrioli, M.G., Vermacotola, S., Peruzzi, L., et al. (2008). A double-blind, parallel, multicenter comparison of l-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in Fragile X syndrome boys. American Journal of Medical Genetics Part A, 146, 803–812.CrossRefGoogle Scholar
Torrioli, M.G., Vemacotola, S., Setini, C., et al. (2010). Treatment with valproic acid ameliorates ADHD symptoms in Fragile X syndrome boys. American Journal of Medical Genetics Part A, 152, 1420–1427.Google Scholar
Tsiouris, J.A. (2010). Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment? Journal of Intellectual Disability Research, 54, 1–16.Google Scholar
Tyrer, P., Oliver-Africano, P.C., Ahmed, Z., et al. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behavior in patients with intellectual disability: a randomized controlled trial. Lancet, 371, 57–63.CrossRefGoogle Scholar
Tyrer, P., Oliver-Africano, P., Romeo, R., et al. (2009). Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomized controlled trial (NACHBID). Health Technology Assessment, 13, 1–54.Google Scholar
Unwin, G.L. and Deb, S. (2008). Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians’ consensus survey. American Journal on Mental Retardation, 113, 19–31.CrossRefGoogle ScholarPubMed
Unwin, G.L. and Deb, S. (2011). Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review. Research in Developmental Disabilities, 332, 2121–2133.Google Scholar
Valdovinos, M.G., Caruso, M., Roberts, C., et al. (2005). Medical and behavioral symptoms as potential medication side effects in adult with development disabilities. American Journal on Mental Retardation, 110, 164–170.2.0.CO;2>CrossRefGoogle Scholar
Ward, F., Tharian, P., Roy, M., et al. (2013). Efficacy of beta blockers in the management of problem behaviors in people with intellectual disabilities: a systematic review. Research in Developmental Disabilities, 34, 4293–4303.CrossRefGoogle ScholarPubMed
Williams, K., Wheeler, D.M., Silove, N., et al. (2010). Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews, 8, CD004677.CrossRefGoogle Scholar
Williams, K., Wray, J.A., Wheeler, D.M. (2012). Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews, 4, CD003495.Google Scholar
Wilner, P. (2015). The neurobiology of aggression: implications for the pharmacotherapy of aggressive challenging behaviour by people with intellectual disabilities. Journal of Intellectual Disability Research, 59(1), 82–92.CrossRefGoogle Scholar
Wilson, J.G., Lott, R.S., Tsai, L. (1998). Side effects: recognition and management. In Reiss, S. and Aman, M.G. (eds.), Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: Ohio State University, Nisonger Center Press.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×